| Josephine Health Llc | |
|
3300 Dairy Rd Titusville FL 32796-1512 | |
| (248) 881-6763 | |
| Not Available |
| Full Name | Josephine Health Llc |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 3300 Dairy Rd, Titusville, Florida |
| Authorized Official Name and Position | Louis Joseph (OWNER) |
| Authorized Official Contact | 2488816763 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Josephine Health Llc 302 E Lakewood Rd West Palm Beach FL 33405-2902 Ph: (248) 881-6763 | Josephine Health Llc 3300 Dairy Rd Titusville FL 32796-1512 Ph: (248) 881-6763 |
| NPI Number | 1619323441 |
|---|---|
| Provider Enumeration Date | 05/11/2016 |
| Last Update Date | 05/11/2016 |
| Medicare PECOS PAC ID | 3870993587 |
|---|---|
| Medicare Enrollment ID | O20210617001800 |
News Archive
Regenstrief Institute and Boomerang Ventures are announcing a partnership to develop and disseminate healthcare solutions to improve the well-being of people around the world.
The U.S. Department of Defense has granted the "Impact Award" to explore new therapeutic options against advanced prostate cancer - scientifically known as castration-resistant or hormone therapy resistant prostate cancer- to a multidisciplinary team of researchers made up of the Prostate Cancer Clinical Research Unit of the Spanish National Cancer Research Center, led by David Olmos, the Prostate Cancer Translational Research Group of the Vall d'Hebron Institute of Oncology, led by Joaquín Mateo, and the Genetics and Solid Tumors Laboratory of the University of Washington, led by Colin Pritchard.
Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.
› Verified 1 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619323441 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | ME121826 (Florida) | Primary |
| Provider Name | Louis Theodore Joseph |
|---|---|
| Provider Type | Practitioner - Psychiatry |
| Provider Identifiers | NPI Number: 1013167170 PECOS PAC ID: 0941471726 Enrollment ID: I20141217001520 |
News Archive
Regenstrief Institute and Boomerang Ventures are announcing a partnership to develop and disseminate healthcare solutions to improve the well-being of people around the world.
The U.S. Department of Defense has granted the "Impact Award" to explore new therapeutic options against advanced prostate cancer - scientifically known as castration-resistant or hormone therapy resistant prostate cancer- to a multidisciplinary team of researchers made up of the Prostate Cancer Clinical Research Unit of the Spanish National Cancer Research Center, led by David Olmos, the Prostate Cancer Translational Research Group of the Vall d'Hebron Institute of Oncology, led by Joaquín Mateo, and the Genetics and Solid Tumors Laboratory of the University of Washington, led by Colin Pritchard.
Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.
› Verified 1 days ago
News Archive
Regenstrief Institute and Boomerang Ventures are announcing a partnership to develop and disseminate healthcare solutions to improve the well-being of people around the world.
The U.S. Department of Defense has granted the "Impact Award" to explore new therapeutic options against advanced prostate cancer - scientifically known as castration-resistant or hormone therapy resistant prostate cancer- to a multidisciplinary team of researchers made up of the Prostate Cancer Clinical Research Unit of the Spanish National Cancer Research Center, led by David Olmos, the Prostate Cancer Translational Research Group of the Vall d'Hebron Institute of Oncology, led by Joaquín Mateo, and the Genetics and Solid Tumors Laboratory of the University of Washington, led by Colin Pritchard.
Two new drugs have gained approval from the US Food and Drug Administration (FDA) – one is an antibiotic from Forest Labs and the other a first-time treatment for a neurological disorder developed by Avanir Pharmaceuticals. Another waiting for approval is Biodel's fast-acting insulin Linjeta. On the other hand seven new drugs got rejected including a diabetes drug from Amylin Pharmaceuticals and weight-loss drugs from Arena Pharmaceuticals and Vivus, respectively.
VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic diseases, today announced that Dr. Rebecca Taub, Senior Vice President Research & Development will present "Liver Directed Beta Agonist for Targeting Cardiometabolic Disease", and will discuss the Company's cardio-metabolic product portfolio, including VIA's inhibitor of 5 Lipoxygenase, its THR Beta Agonist, and its DGAT1 development programs, at the Cambridge Healthtech Institute Seventh International Discovery on Target 2009 program, on November 3, 2009 in Boston, MA.
› Verified 1 days ago
Thomas F. Guidera, Ph.d, P.a. Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 1777 Garden Street, Titusville, FL 32796 Phone: 321-268-5682 Fax: 321-268-5683 | |
Family Builders Counseling Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1010 Norwood Ave, Titusville, FL 32796 Phone: 321-432-8295 Fax: 321-267-8491 | |
Alpha Medical Consulting Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 123 S Park Ave, Titusville, FL 32796 Phone: 321-298-5531 | |
Ref Nurse Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 605 S Palm Ave, Titusville, FL 32796 Phone: 321-289-2818 | |
Dj Sustainable Progress Consulting Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 2503 S Washington Ave Ste 1264, Titusville, FL 32780 Phone: 407-915-1877 Fax: 877-915-7798 | |
Space Coast Health Centers Inc Mental Health Clinic Medicare: Medicare Enrolled Practice Location: 951 N Washington Ave Ste 100, Titusville, FL 32796 Phone: 386-852-9565 | |
Latino Leadership, Inc. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4403 S Hopkins Ave, Titusville, FL 32780 Phone: 407-895-0801 Fax: 407-895-0803 |